Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Chubb
Harvard Business School
US Department of Justice
US Army
Fish and Richardson

Generated: July 19, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 211367

Try a free trialSee Plans and Pricing

« Back to Dashboard

NDA 211367 describes SLYND, which is a drug marketed by Exeltis Usa Inc and is included in one NDA. Additional details are available on the SLYND profile page.

The generic ingredient in SLYND is drospirenone. There are eleven drug master file entries for this compound. Additional details are available on the drospirenone profile page.
Summary for 211367
Tradename:SLYND
Applicant:Exeltis Usa Inc
Ingredient:drospirenone
Patents:0
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 211367
Generic Entry Date for 211367*:
➤ Sign Up
Constraining patent/regulatory exclusivity:
NEW PRODUCT
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 211367

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength4MG
Approval Date:May 23, 2019TE:RLD:Yes
Regulatory Exclusivity Expiration:May 23, 2022
Regulatory Exclusivity Use:NEW PRODUCT

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Julphar
Mallinckrodt
Merck
Fish and Richardson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
Major Patent Expirations 2019 - 2020
 NCE-1 Generic Application Dates 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.
Links

Follow DrugPatentWatch: